CL2019001049A1 - Vacuna contra parvovirus porcino. - Google Patents

Vacuna contra parvovirus porcino.

Info

Publication number
CL2019001049A1
CL2019001049A1 CL2019001049A CL2019001049A CL2019001049A1 CL 2019001049 A1 CL2019001049 A1 CL 2019001049A1 CL 2019001049 A CL2019001049 A CL 2019001049A CL 2019001049 A CL2019001049 A CL 2019001049A CL 2019001049 A1 CL2019001049 A1 CL 2019001049A1
Authority
CL
Chile
Prior art keywords
residue
subject
amino acid
ppv
invention refers
Prior art date
Application number
CL2019001049A
Other languages
English (en)
Inventor
Eric Martin Vaughn
Scott Eugene Bucklin
Troy James KAISER
Jeremy Kroll
Philip Utley
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of CL2019001049A1 publication Critical patent/CL2019001049A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14323—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE, ENTRE OTRAS COSAS, A UNA PROTEÍNA VIRAL 2 (VP2) DE PARVOVIRUS PORCINO (PPV) QUE TIENE, EN LA POSICIÓN DE AMINOÁCIDO 228, UN RESIDUO DE ÁCIDO GLUTÁMICO O UN RESIDUO DE GLUTAMATO, Y/O EN LA POSICIÓN DE AMINOÁCIDO 414, UN RESIDUO DE SERINA, Y/O EN LA POSICIÓN DE AMINOÁCIDO 419, UN RESIDUO DE GLUTAMINA, Y/O EN LA POSICIÓN DE AMINOÁCIDO 436, UN RESIDUO DE TREONINA. LA PRESENTE INVENCIÓN TAMBIÉN SE REFIERE A COMPOSICIONES INMUNÓGENAS QUE COMPRENDEN DICHA PROTEÍNA VIRAL 2 (VP2) DE PPV. ASIMISMO, LA PRESENTE INVENCIÓN SE REFIERE A MÉTODOS PARA INMUNIZAR UN SUJETO, QUE COMPRENDEN ADMINISTRAR A DICHO SUJETO LA COMPOSICIÓN INMUNÓGENA DE LA PRESENTE INVENCIÓN. ADEMÁS, LA PRESENTE INVENCIÓN SE REFIERE A MÉTODOS PARA TRATAR O PREVENIR SIGNOS CLÍNICOS CAUSADOS POR UNA INFECCIÓN POR PPV EN UN SUJETO QUE LO NECESITA, EN DONDE EL MÉTODO COMPRENDE ADMINISTRAR AL SUJETO UNA CANTIDAD TERAPÉUTICAMENTE EFICAZ DE UNA COMPOSICIÓN INMUNÓGENA DE ACUERDO CON LA PRESENTE INVENCIÓN.
CL2019001049A 2016-11-03 2019-04-17 Vacuna contra parvovirus porcino. CL2019001049A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16197091 2016-11-03

Publications (1)

Publication Number Publication Date
CL2019001049A1 true CL2019001049A1 (es) 2019-08-16

Family

ID=57223617

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001049A CL2019001049A1 (es) 2016-11-03 2019-04-17 Vacuna contra parvovirus porcino.

Country Status (15)

Country Link
US (2) US10485866B2 (es)
EP (1) EP3534945A1 (es)
JP (2) JP6876127B2 (es)
CN (1) CN109803678B (es)
AU (1) AU2017353378B2 (es)
BR (1) BR112019009133A2 (es)
CA (1) CA3042573A1 (es)
CL (1) CL2019001049A1 (es)
EA (1) EA201991065A1 (es)
MX (1) MX2019005137A (es)
MY (1) MY191490A (es)
PH (1) PH12019500954A1 (es)
TW (1) TWI781962B (es)
UA (1) UA127859C2 (es)
WO (1) WO2018083154A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11730806B2 (en) 2016-11-03 2023-08-22 Boehringer Ingelheim Vetmedica Gmbh Methods of manufacturing an immunogenic composition comprising a recombinant protein

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140170180A1 (en) 2012-12-17 2014-06-19 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5a, methods of use and vaccine
EP3534945A1 (en) 2016-11-03 2019-09-11 Boehringer Ingelheim Vetmedica GmbH Vaccine against porcine parvovirus
US11013796B2 (en) 2018-08-30 2021-05-25 Iowa State University Research Foundation, Inc. Porcine parainfluenza virus type 1 isolates and immunogenic compositions therefrom
KR102117811B1 (ko) * 2018-12-05 2020-06-02 대한민국(농림축산식품부 농림축산검역본부장) 재조합 돼지파보바이러스 항원 단백질 및 이의 용도
CN114222579A (zh) 2019-04-04 2022-03-22 勃林格殷格翰动物保健美国有限公司 猪圆环病毒3型（pcv3）疫苗及其生产和用途
CN110845580A (zh) * 2019-11-05 2020-02-28 中国农业科学院兰州兽医研究所 一种猪细小病毒样颗粒的组装及其免疫原性鉴定方法
CN114480439A (zh) * 2022-02-23 2022-05-13 成都史纪生物制药有限公司 一种猪细小病毒vp2蛋白基因及其应用
CN117866053A (zh) * 2024-01-10 2024-04-12 武汉珈创生物技术股份有限公司 同时检测多种猪细小病毒的多克隆抗体及其制备和应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US382425A (en) 1888-05-08 Brandt
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
EP0117767A1 (en) 1983-01-07 1984-09-05 Mgi Pharma, Inc. Production of parvovirus subunit vaccines
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
EP0322417A1 (en) 1986-09-08 1989-07-05 Applied Biotechnology, Inc. Empty viral capsid vaccines
IL84154A0 (en) 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
EP0386185A1 (fr) 1988-07-29 1990-09-12 IntraCel Corporation Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0465529T3 (da) 1989-03-21 1998-10-05 Vical Inc Ekspression af exogene polynukleotidsekvenser i et hvirveldyr
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
GB9001766D0 (en) 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
ES2026827A6 (es) 1991-03-26 1992-05-01 Ercros Sa Procedimiento para la produccion de una vacuna subunidad contra el parvovirus porcino.
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
EP0620277A1 (en) 1993-03-18 1994-10-19 Merck & Co. Inc. Nucleic acid pharmaceuticals
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
ATE475668T1 (de) 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
AU694519B2 (en) 1994-04-29 1998-07-23 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
CA2215162A1 (en) 1995-03-23 1996-09-26 Cantab Pharmaceuticals Research Limited Vectors for gene delivery
JP2002512501A (ja) 1996-07-03 2002-04-23 メリアル インコーポレイテッド 外来性ｄｎａを含む組換えイヌアデノウィルス（ｃａｖ）
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
FR2789695B1 (fr) * 1999-02-11 2003-03-07 Merial Sas Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs
RU2269361C2 (ru) 2004-03-25 2006-02-10 Федеральное государственное учреждение "Федеральный центр охраны здоровья животных" (ФГУ ВНИИЗЖ) Вакцина ассоциированная эмульсионная инактивированная против репродуктивно-респираторного синдрома и парвовирусной инфекции свиней
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
DK2542260T3 (en) 2010-03-05 2016-06-06 Intervet Int Bv Recombinantly weakening parvovirus
TWI508974B (zh) 2010-12-22 2015-11-21 Sbc Virbac Ltd 豬第二型環狀病毒(Porcine Circovirus Type 2)、含彼之免疫組合物、檢測套組及其應用
CN102488895A (zh) 2011-12-30 2012-06-13 重庆大学 一种猪圆环病毒、猪细小病毒、猪繁殖与呼吸综合症病毒三联病毒样颗粒疫苗及其制备方法
CN102727881A (zh) 2012-07-04 2012-10-17 广东大华农动物保健品股份有限公司 高致病性猪繁殖与呼吸综合征jxa1-r株-猪细小病毒病二联活疫苗及其制备方法和应用
US20140170180A1 (en) 2012-12-17 2014-06-19 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5a, methods of use and vaccine
US20140234354A1 (en) 2013-02-15 2014-08-21 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5b, methods of use and vaccine
CN104288760A (zh) 2013-07-18 2015-01-21 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
JP6778104B2 (ja) * 2013-10-02 2020-10-28 ベーリンガー・インゲルハイム・アニマル・ヘルス・ユーエスエー・インコーポレイテッドＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｕｓａ Ｉｎｃ． Ｐｃｖ２ ｏｒｆ２タンパク質変種および前記を含むウイルス様粒子
CN106039304B (zh) * 2016-05-28 2021-02-05 青岛易邦生物工程有限公司 一种猪细小病毒、猪流行性腹泻、大肠埃希氏菌三联疫苗
EP3534945A1 (en) * 2016-11-03 2019-09-11 Boehringer Ingelheim Vetmedica GmbH Vaccine against porcine parvovirus
CA3042584A1 (en) 2016-11-03 2018-05-11 Boehringer Ingelheim Vetmedica Gmbh Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11730806B2 (en) 2016-11-03 2023-08-22 Boehringer Ingelheim Vetmedica Gmbh Methods of manufacturing an immunogenic composition comprising a recombinant protein

Also Published As

Publication number Publication date
TWI781962B (zh) 2022-11-01
AU2017353378A1 (en) 2019-05-02
CA3042573A1 (en) 2018-05-11
WO2018083154A1 (en) 2018-05-11
US10799578B2 (en) 2020-10-13
MX2019005137A (es) 2019-06-20
BR112019009133A2 (pt) 2019-07-16
AU2017353378B2 (en) 2024-03-14
US20180133309A1 (en) 2018-05-17
JP2020500012A (ja) 2020-01-09
US10485866B2 (en) 2019-11-26
EA201991065A1 (ru) 2019-11-29
TW201829446A (zh) 2018-08-16
CN109803678A (zh) 2019-05-24
US20200030438A1 (en) 2020-01-30
MY191490A (en) 2022-06-28
JP2021097679A (ja) 2021-07-01
PH12019500954A1 (en) 2019-12-02
KR20190089899A (ko) 2019-07-31
JP6876127B2 (ja) 2021-05-26
UA127859C2 (uk) 2024-01-31
CN109803678B (zh) 2023-08-22
EP3534945A1 (en) 2019-09-11

Similar Documents

Publication Publication Date Title
CL2019001049A1 (es) Vacuna contra parvovirus porcino.
CY1123315T1 (el) Απο-ανοσοποιημενα, ικριωματα υπομοναλων α τοξινων shiga και μορια στοχευσης-κυτταρων περιλαμβανοντας τα ιδια
EA202092808A1 (ru) Вакцины на основе наночастиц с новыми структурными компонентами
CL2017002345A1 (es) Un nuevo complejo que comprende un péptido de penetración celular, una molécula cargo y un agonista peptídico de tlr
UY37998A (es) Agentes antivirales contra la hepatitis b
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
CL2018002692A1 (es) Vacuna bivalente contra el virus de gripe porcina.(divisional solicitud 201701961)
EA201990071A1 (ru) Композиция пептидной вакцины
DOP2022000293A (es) Análogos de nucleósido de 1’-ciano y usos de los mismos
CO2018010874A2 (es) Vacuna de virus de zika atenuado vivo
ECSP21042554A (es) Proteínas f de prefusión del vrs estabilizadas
PE20190110A1 (es) Proteinas f de prefusion del vrs estabilizadas
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
AR109538A1 (es) Vacuna contra la gripe porcina
AR101814A1 (es) Partícula de tipo virus flavivirus
CR20230100A (es) Compuestos fosfolípidos y usos de los mismos
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
EA201991023A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту
CL2023001062A1 (es) Compuestos fosfolípidos y usos de estos
CL2021003063A1 (es) Arn terapéutico para cáncer de ovario
CL2017003201A1 (es) Variantes de il-37
BR112019006802A2 (pt) compostos e métodos para diagnóstico e tratamento de infecções virais
CO2021005066A2 (es) Vacuna de ibv 4/91 con proteína espicular heteróloga
CO6362049A2 (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo
CO2020009043A2 (es) Anticuerpos humanos contra hemaglutinina de influenza